Estrogen and cancer

Annual Review of Physiology

Volumn 75, Issue , 2013, Pages 225-240

  Liang, Jing ^a,b   Shang, Yongfeng ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Breast cancer; Endocrine resistance; Estrogen receptor; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; FULVESTRANT; HISTONE DEACETYLASE INHIBITOR; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

ANDROGEN DEPRIVATION THERAPY; BREAST CANCER; CANCER CELL; CANCER HORMONE THERAPY; CANCER RESISTANCE; CARCINOGENESIS; CHEMORADIOTHERAPY; DRUG COST; DRUG POTENTIATION; DRUG STRUCTURE; ENDOMETRIUM CANCER; EPIGENETICS; ESTROGEN METABOLISM; FRACTURE; HUMAN; METASTASIS; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HUMANS; NEOPLASMS; RECEPTORS, ESTROGEN; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84873675307     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-030212-183708     Document Type: Review

References (89)

1. Koos RD. 2011. Minireview: putting physiology back into estrogens' mechanism of action. Endocrinology 152:4481-88
2. Shang Y. 2006. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat. Rev. Cancer 6:360-68
3. Shang Y. 2007. Hormones and cancer. Cell Res. 17:277-79
4. Prentice RL, Anderson GL. 2008. The women's health initiative: lessons learned. Annu. Rev. Public Health 29:131-50
5. Auchus ML, Auchus RJ. 2012. Human steroid biosynthesis for the oncologist. J. Investig. Med. 60:495-503
6. Miller WL, Auchus RJ. 2011. The molecular biology, biochemistry, and physiology of human steroido-genesis and its disorders. Endocr. Rev. 32:81-151
7. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. 2011. Aromatase, aromatase inhibitors, and breast cancer. J. Steroid Biochem. Mol. Biol. 125:13-22
8. Brueggemeier RW. 2001. Aromatase, aromatase inhibitors, and breast cancer. Am. J. Ther. 8:333-44
9. Cleary MP, Grossmann ME. 2009. Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 150:2537-42
10. Wibowo E, Schellhammer P, Wassersug RJ. 2011. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy. J. Urol. 185:17-23
11. Folkerd EJ, Dowsett M. 2010. Influence of sex hormones on cancer progression. J. Clin. Oncol. 28:4038-44
12. Jensen EV, Jacobson HI, Walf AA, Frye CA. 2010. Estrogen action: a historic perspective on the implications of considering alternative approaches. Physiol. Behav. 99:151-62
13. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, et al. 2007. Estrogen receptors: How do they signal and what are their targets. Physiol. Rev. 87:905-31
14. Bjornstrom L, Sjoberg M. 2005. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 19:833-42
15. Hammes SR, Levin ER. 2011. Minireview: recent advances in extranuclear steroid receptor actions. Endocrinology 152:4489-95
16. Thomas C, Gustafsson JA. 2011. The different roles of ER subtypes in cancer biology and therapy. Nat. Rev. Cancer 11:597-608
17. Nilsson S, Koehler KF, Gustafsson JA. 2011. Development of subtype-selective oestrogen receptor-based therapeutics. Nat. Rev. Drug Discov. 10:778-92
18. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. 1996. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 93:5925-30
19. Musgrove EA, Sutherland RL. 2009. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9:631-43
20. /- diindolylmethane is mediated by cross talk between the protein kinase A and mitogen-activated protein kinase signaling pathways. Mol. Endocrinol. 18:291-302
21. Stender JD, Kim K, Charn TH, Komm B, Chang KC, et al. 2010. Genome-wide analysis of estrogen receptor ex DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol. Cell. Biol. 30:3943-55
22. Jerry DJ, Dunphy KA, Hagen MJ. 2010. Estrogens, regulation of p53 and breast cancer risk: a balancing act. Cell. Mol. Life Sci. 67:1017-23
23. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M. 2000. Effect of single and compound knockouts of estrogen receptors cx(ERcx) and |3 (ER|3) on mouse reproductive phenotypes. Development 127:4277-91
24. Imamov O, Lopatkin NA, Gustafsson JA. 2004. Estrogen receptor |3 in prostate cancer. N Engl. J. Med. 351:2773-74
25. Forster C, Makela S, Warri A, Kietz S, Becker D, et al. 2002. Involvement of estrogen receptor |3 in terminal differentiation of mammary gland epithelium. Proc. Natl. Acad. Sci. USA 99:15578-83
26. Antal MC, Krust A, Chambon P, Mark M. 2008. Sterility and absence of histopathological defects in nonreproductive organs of a mouse ER|3-null mutant. Proc. Natl. Acad. Sci. USA 105:2433-38
27. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. 2005. Identification, cloning, and expression of human estrogen receptor-cx36, a novel variant of human estrogen receptor-cx66. Biochem. Biophys. Res. Commun. 336:1023-27
28. Jordan VC, O'Malley BW. 2007. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J. Clin. Oncol. 25:5815-24
29. Li S, Shang Y. 2007. Regulation of SRC family coactivators by post-translational modifications. Cell. Signal. 19:1101-12
30. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, et al. 1997. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389:194-98
31. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, et al. 1997. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569-80
32. Liang J, Zhang H, Zhang Y, Zhang Y, Shang Y. 2009. GAS, a new glutamate-rich protein, interacts differentially with SRCs and is involved in oestrogen receptor function. EMBO Rep. 10:51-57
33. Tsai HW, Katzenellenbogen JA, Katzenellenbogen BS, Shupnik MA. 2004. Protein kinase A activation of estrogen receptor ex transcription does not require proteasome activity and protects the receptor from ligand-mediated degradation. Endocrinology 145:2730-38
34. Bunone G, Briand PA, Miksicek RJ, Picard D. 1996. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:2174-83
35. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, et al. 2001. Direct acetylation of the estrogen receptor ex hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem. 276:18375-83
36. Berry NB, Fan M, Nephew KP. 2008. Estrogen receptor-tx hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome. Mol. Endocrinol. 22:1535-51
37. Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L. 2011. Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr. Rev. 32:597-622
38. Chen D, Ma H, Hong H, Koh SS, Huang SM, et al. 1999. Regulation of transcription by a protein methyltransferase. Science 284:2174-77
39. Schurter BT, Koh SS, Chen D, Bunick GJ, Harp JM, et al. 2001. Methylation of histone H3 by coactivator-associated arginine methyltransferase 1. Biochemistry 40:5747-56
40. Chevillard-Briet M, Trouche D, Vandel L. 2002. Control of CBP co-activating activity by arginine methylation. EMBO J. 21:5457-66
41. Naeem H, Cheng D, Zhao Q, Underhill C, Tini M, et al. 2007. The activity and stability of the tran-scriptional coactivator p/CIP/SRC-3 are regulated by CARM1-dependent methylation. Mol. Cell. Biol. 27:120-34
42. Sims RJ 3rd, Rojas LA, Beck D, Bonasio R, Schuller R, et al. 2011. The C-terminal domain of RNA polymerase II is modified by site-specific methylation. Science 332:99-103
43. Carascossa S, Dudek P, Cenni B, Briand PA, Picard D. 2010. CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor αby cAMP. Genes Dev. 24:708-19
44. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. 2000. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-52
45. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, et al. 2006. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 38:1289-97
46. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, et al. 2005. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122:33-43
47. Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, et al. 2009. An oestrogen-receptor-α-bound human chro-matin interactome. Nature 462:58-64
48. Zhao C, Putnik M, Gustafsson J-A, Dahlman-Wright K. 2009. Microarray analysis of altered gene expression in ERβ-overexpressing HEK293 cells. Endocrine 36:224-32
49. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. 2011. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 11:558-72
50. Caldon CE, Sutherland RL, Musgrove E. 2010. Cell cycle proteins in epithelial cell differentiation: implications for breast cancer. Cell Cycle 9:1918-28
51. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. 2005. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr. Relat. Cancer 12(Suppl. 1):47-59
52. Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, et al. 2011. Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol. Endocrinol. 25:1527-38
53. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. 2004. Estrogen receptor βinhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. USA 101:1566-71
54. Gompel A, Somai S, Chaouat M, Kazem A, Kloosterboer HJ, et al. 2000. Hormonal regulation of apoptosis in breast cells and tissues. Steroids 65:593-98
55. Ariazi EA, Cunliffe HE, Lewis-Wambi JS, Slifker MJ, Willis AL, et al. 2011. Estrogen induces apopto-sis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc. Natl. Acad. Sci. USA 108:18879-86
56. Lewis-Wambi JS, Jordan VC. 2009. Estrogen regulation of apoptosis: How can one hormone stimulate and inhibit? Breast Cancer Res. 11:206
57. Vasconsuelo A, Pronsato L, Ronda AC, Boland R, Milanesi L. 2011. Role of 17β-estradiol and testosterone in apoptosis. Steroids 76:1223-31
58. Miller VM, Duckles SP. 2008. Vascular actions of estrogens: functional implications. Pharmacol. Rev. 60:210-41
59. Bendrik C, Dabrosin C. 2009. Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J. Immunol. 182:371-78
60. Lindahl G, Saarinen N, Abrahamsson A, Dabrosin C. 2012. Tamoxifen, flaxseed, and the lignan entero-lactone increase stroma-and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer. Cancer Res. 71:51-60
61. McCune K, Mehta R, Thorat MA, Badve S, Nakshatri H. 2010. Loss of ERαand FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model. Oncol. Rep. 24:1233-39
62. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, et al. 2007. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat. Cell Biol. 9:470-78
63. Guttilla IK, Adams BD, White BA. 2012. ERα, microRNAs, and the epithelial-mesenchymal transition in breast cancer. Trends Endocrinol. Metab. 23:73-82
64. Saha Roy S, Vadlamudi RK. 2012. Role of estrogen receptor signaling in breast cancer metastasis. Int. J. Breast Cancer 2012:654698
65. Bai J, Uehara Y, Montell DJ. 2000. Regulation of invasive cell behavior by taiman, a Drosophila protein related to AIB1, a steroid receptor coactivator amplified in breast cancer. Cell 103:1047-58
66. Yan J, Erdem H, Li R, Cai Y, Ayala G, et al. 2008. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 68:5460-68
67. Lydon JP, O'Malley BW. 2011. Minireview: steroid receptor coactivator-3: a multifarious coregulator in mammary gland metastasis. Endocrinology 152:19-25
68. Griggs JJ, Somerfield MR, Anderson H, Henry NL, Hudis CA, et al. 2011. American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. J. Clin. Oncol. 29:3939-42
69. Zhou WB, Ding Q, Chen L, Liu XA, Wang S. 2011. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. Breast Cancer Res. Treat. 128:625-31
70. Wardell SE, Marks JR, McDonnell DP. 2011. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem. Pharmacol. 82:122-30
71. Wittmann BM, Sherk A, McDonnell DP. 2007. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res. 67:9549-60
72. 2006. STAR trial reports. Eur. J. Cancer 42:1694
73. McDonnell DP, Wardell SE. 2010. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr. Opin. Pharmacol. 10:620-28
74. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, et al. 1998. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-37
75. Shang Y, Brown M. 2002. Molecular determinants for the tissue specificity of SERMs. Science 295:2465-68
76. Wu H, Chen Y, Liang J, Shi B, Wu G, et al. 2005. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438:981-87
77. Thomas S, Thurn KT, Bicaku E, Marchion DC, Munster PN. 2011. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res. Treat. 130:437-47
78. Jordan VC. 2007. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 72:829-42
79. Hoskins JM, Carey LA, McLeod HL. 2009. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9:576-86
80. Green KA, Carroll JS. 2007. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat. Rev. Cancer 7:713-22
81. Burwinkel B, Wirtenberger M, Klaes R, Schmutzler RK, Grzybowska E, et al. 2005. Association of NCOA3 polymorphisms with breast cancer risk. Clin. Cancer Res. 11:2169-74
82. Bergamaschi A, Katzenellenbogen BS. 2012. Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Oncogene 31:39-47
83. Veeck J, Esteller M. 2010. Breast cancer epigenetics: from DNA methylation to microRNAs. J. Mammary Gland Biol. Neoplasia 15:5-17
84. Kelly TK, De Carvalho DD, Jones PA. 2010. Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 28:1069-78
85. Pathiraja TN, Stearns V, Oesterreich S. 2010. Epigenetic regulation in estrogen receptor positive breast cancer-role in treatment response. J. Mammary Gland Biol. Neoplasia 15:35-47
86. Reis-Filho JS, Pusztai L. 2011. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378:1812-23
87. Dalvai M, Bystricky K. 2010. The role of histone modifications and variants in regulating gene expression in breast cancer. J. Mammary Gland Biol. Neoplasia 15:19-33
88. Badia E, Oliva J, Balaguer P, Cavailles V. 2007. Tamoxifen resistance and epigenetic modifications in breast cancer cell lines. Curr. Med. Chem. 14:3035-45
89. Lin S, Lin CJ, Hsieh DP, Li LA. 2012. ERα phenotype, estrogen level, and benzo[a]pyrene exposure modulate tumor growth and metabolism of lung adenocarcinoma cells. Lung Cancer 75:285-92